×
Click if you have patients on Pushtronex® system and need information on transition to a new device
AMGEN® SupportPlus | Repatha® (evolocumab)
INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease.. READ MORE

    • For US healthcare professionals

    Encourage Patients to Sign Up for AMGEN® SupportPlus

    Out-of-Pocket Cost Icon

    Reduce out-of-pocket costs for patients

    Amgen® Nurse Icon

    Help empower patients with Amgen® Nurse Partners

    Resources Icon

    Resources designed to support access

    Email your appropriate patients a direct link to enroll in the services provided by Amgen® SupportPlus

    We’re Right Here, Right When You Need Us

    Personalized support that you and your patients can count on across Amgen® therapies.

    Watch the video to learn more about Amgen SupportPlus.
    Out-of-Pocket Cost Icon

    Financial Support Resources

    We know every patient has unique needs. And we’re here to provide financial support information and resources, regardless of their current financial situation or type of insurance they have.

    • Commercial Insurance

    • Government Insurance

    • Uninsured

    Repatha® (evolocumab) Co-Pay Card

    Repatha® Co-Pay Card

    Your commercially insured patients may pay as little as $15* per month with the Repatha® Co-Pay Card. Encourage them to enroll today!

    *Eligibility criteria and program maximums apply. Please see full Terms and Conditions at Repatha.com/copaytcs

    Medicaid

    ~99% of prescriptions cost patients $10 or less*

    Medicare

    ~73% of Repatha® prescriptions cost Medicare patient $50 or less*,†

    *Based on IQVIA claims data from 1/1/2023 to 12/31/2023 using the respective Medicare or Medicaid data.

    †The patient’s out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in.

    Learn how Amgen® SupportPlus can help your patients access their prescribed medication.

    Call Amgen® SupportPlus at

    1-844-REPATHA (1-844-737-2842),
    Monday – Friday 8:00am – 8:00pm ET to learn more.

    *Based on IQVIA claims data from 1/1/2023 to 12/31/2023 using the respective Medicare or Medicaid data.

    †The patient’s out-of-pocket costs can vary throughout the year depending on which phase of the Part D benefit the patient is currently in.

    What if my patient doesn’t have private or commercial insurance?

    Amgen® SupportPlus can provide your patients with information about independent nonprofit foundations that may be able to help*

    *Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over the programs and provides information as a courtesy only.

    Learn how Amgen® SupportPlus can help your patients access their prescribed medication.

    Call Amgen® SupportPlus at

    1-844-REPATHA (1-844-737-2842),
    Monday – Friday 8:00am – 8:00pm ET to learn more.
    Amgen® Nurse Icon

    Amgen® Nurse Partners

    Dedicated Amgen Nurse Partners can offer supplemental support to help your patients on their journey.

    Hypothetical Amgen® Nurse Partner Helping a Patient

    Amgen Nurse Partners can provide supplemental support, including:

    • Supplemental injection education and support
    • Guidance on resources that may help lower out-of-pocket medication costs
    • Assistance to help your patients stay on track with their medication
    • Answers to questions about Amgen SupportPlus

    Your patients can enroll in the Amgen Nurse Partner Program online at repatha.com or by calling 1-844-REPATHA (1-844-737-2842).

    Amgen Nurse Partners are only available to patients that are prescribed certain Amgen products. They are not part of your patient’s treatment team and do not provide medical advice, nursing, or case management services. Amgen Nurse Partners will not inject patients with Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

    Amgen® Access Specialist Icon

    Field Access Specialists

    A Field Access Specialist can provide live or virtual coverage and access resources to support your patients.

    Hypothetical Amgen® Access Specialist

    Contact your Field Access Specialist for live or virtual support, that includes:

    • Help with navigating prior authorization, appeals, and fulfillment processes
    • Educating on payer requirements and necessary documentation for individual patient support
    • Answers to general questions about Amgen SupportPlus programs and other available resources
    • Navigating the benefit verification process

    Your Amgen representative can connect you with a Field Specialist or call 1-844-REPATHA Monday – Friday 8:00am – 8:00pm ET

    To view the Repatha® Co-Pay Card Terms and Conditions, please visit Repatha.com/copaytcs.

    Important Safety Information

    Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

    Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

    Adverse Reactions in Primary Hyperlipidemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

    From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

    Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

    Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

    Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

    Indications

    Repatha® is indicated:

    • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease
    • as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

    Please see full Prescribing Information.

    Important Safety Information

    Back To Top